首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1683386

全球神經系統疾病數位治療市場 - 2025 至 2033 年

Global Digital Therapeutics for Neurological Disorders Market - 2025-2033

出版日期: 2025年03月20日 | 出版商:

DataM Intelligence | 英文 166 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球神經系統疾病數位治療市場規模達 2.4694 億美元，預計到 2033 年將達到 5.0436 億美元，2025-2033 年預測期內的複合年成長率為 8.3%。

神經系統疾病的數位療法是指利用行動應用程式、軟體程式、虛擬實境 (VR)、穿戴式裝置和其他連接裝置等數位平台來預防、管理或治療神經系統疾病的實證治療介入措施。這些治療通常採用人工智慧 (AI)、機器學習 (ML)、巨量資料分析和神經刺激等先進技術，提供客製化、即時且通常非侵入性的護理。

數位療法旨在提供精準、個人化和以患者為中心的干涉，重點關注受神經系統疾病影響的認知、運動和行為功能。它們可以與傳統治療方法結合或作為獨立療法，可能涉及自我管理、復原、症狀監測或行為矯正。這些數位解決方案旨在改善臨床結果，同時與傳統治療相比提供更高的可近性、便利性和更低的成本。

市場動態：

促進因素與約束因素

轉向居家護理和遠端病患監控

向家庭護理和遠端病人監控的轉變極大地推動了神經系統疾病數位治療市場的成長，預計將在預測期內推動市場的發展。居家照護使患者無需頻繁去醫院即可接受治療，這對於患有帕金森氏症、阿茲海默症或多發性硬化症等慢性神經系統疾病的患者尤其重要。透過數位療法，患者可以使用行動應用程式、穿戴式裝置或其他數位平台在家中管理他們的症狀。

例如，Akili Interactive 的注意力不足過動症 (ADHD) 數位療法 EndeavorRx 是一種可以在家使用的解決方案，患者無需到診所就診即可接受治療，從而減輕了患者和醫療保健提供者的負擔。

遠端病人監控有助於克服地理障礙，使農村或服務不足地區的患者無需長途跋涉即可獲得先進的神經系統護理。數位治療解決方案（包括用於症狀追蹤和治療依從性的應用程式）可以在任何地方使用，彌補獲得專科護理方面的差距。

數位療法旨在透過提供自我管理應用程式、提醒和個人化介入等工具來吸引患者。這提高了患者對治療方案的依從性，特別是對於需要長期治療的慢性神經系統疾病患者。許多數位解決方案的互動性和遊戲化特性增強了參與度，使患者更容易堅持規定的治療方案並定期追蹤他們的進展。

例如，2023 年 10 月，BeCareLink 推出了一款新的定量和人工智慧 (AI) 應用程式，以支援一般神經系統檢查，以篩選和監測神經系統疾病。這款名為 BeCare Neuro Link 的新行動應用程式旨在對神經系統疾病患者或患有潛在神經系統疾病的患者進行遠端、客觀和全面的評估。

資料隱私和網路安全問題

資料隱私和網路安全是神經系統疾病數位治療市場的主要關注點，因為這些平台依賴敏感患者資料的收集、儲存和分析，包括個人健康資訊 (PHI)、認知評估和即時健康監測。數位治療平台通常將患者資料儲存在基於雲端的系統或其他線上基礎設施中，這使得它們容易受到網路攻擊。敏感健康資料的洩漏可能導致身分盜竊、金融詐欺甚至醫療詐欺。

例如，根據《HIPAA雜誌》報導，2023 年 8 月，人們發現有 2,300 萬份醫療記錄被洩露。在過去的 12 個月中，平均每月有 9,989,003 份醫療記錄被洩露。截至 2024 年 8 月 31 日的一年中，已發生 491 起涉及 500 條或更多記錄的資料外洩事件，已知洩漏的記錄至少有 58,668,002 則。 2024 年的平均洩漏記錄規模目前為 119,487 筆記錄，中位洩漏記錄規模為 4,109 筆記錄。

市場領導者和先驅者
- 新興先鋒和傑出參與者
- 擁有最大銷售品牌的既定領導者
- 擁有成熟產品的市場領導者
CXO 觀點
最新進展與突破
案例研究/正在進行的研究
監管和報銷情況
- 北美洲
- 歐洲
- 亞太地區
- 拉丁美洲
- 中東和非洲
波特五力分析
供應鏈分析
專利分析
SWOT 分析
未滿足的需求和差距
市場進入和擴張的推薦策略
情境分析：最佳情況、基本情況和最壞情況預測
定價分析和價格動態
關鍵意見領袖

第 5 章：神經系統疾病數位治療市場（依產品類型）

軟體治療學
穿戴式裝置

第 6 章：神經系統疾病數位治療市場（依疾病類型）

神經退化性疾病
- 阿茲海默症
- 帕金森氏症
- 多發性硬化症
- 亨丁頓舞蹈症
- 其他
精神健康障礙
- 沮喪
- 焦慮
- 創傷後壓力症候群
- 躁鬱症
- 強迫症 (OCD)
- 其他
中風和腦血管疾病
睡眠障礙
- 失眠
- 睡眠呼吸中止症
- 其他
認知障礙
其他

第 7 章：神經系統疾病數位治療市場（按最終用戶分類）

醫院
專科診所
神經復健中心
家庭護理設置
其他

第 8 章：神經系統疾病數位治療市場，按區域市場分析和成長機會

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
拉丁美洲
- 墨西哥
- 巴西
- 阿根廷
- 拉丁美洲其他地區
亞太
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲

第9章：競爭格局與市場定位

競爭概況和主要市場參與者
市佔率分析與定位矩陣
策略夥伴關係、併購
產品組合和創新的關鍵發展
公司基準化分析

第10章：公司簡介

Akili, Inc.

公司概況
產品組合
- 產品描述
- 產品關鍵績效指標 (KPI)
- 歷史和預測產品銷售量
- 產品銷售量
財務概覽
- 公司收入
- 地區收入佔有率
- 收入預測
主要進展
- 合併與收購
- 關鍵產品開發活動
- 監管部門批准等
SWOT 分析

Click Therapeutics, Inc.
BigHealth
Apple Inc.
MindMaze Inc
NeuroPace, Inc.
NeurologyToolKit
Matoph Labs eU
Fullpower Technologies, Inc.
Neybox Digital Ltd.

第 11 章：假設與研究方法

資料收集方法
數據三角測量
預測技術
數據驗證和確認

第 12 章：附錄

簡介目錄

Product Code: HCIT9333

The global digital therapeutics for neurological disorders market reached US$ 246.94 million in 2024 and is expected to reach US$ 504.36 million by 2033, growing at a CAGR of 8.3% during the forecast period 2025-2033.

Digital therapeutics for neurological disorders refer to evidence-based therapeutic interventions that leverage digital platforms such as mobile apps, software programs, virtual reality (VR), wearables and other connected devices to prevent, manage or treat neurological conditions. These treatments are often powered by advanced technologies such as artificial intelligence (AI), machine learning (ML), big data analytics and neurostimulation to deliver tailored, real-time and often non-invasive care.

Digital therapeutics are designed to provide precise, personalized and patient-centered interventions, focusing on cognitive, motor and behavioral functions that are impacted by neurological disorders. They can be used in conjunction with traditional treatments or as standalone therapies and may involve self-management, rehabilitation, symptom monitoring or behavior modification. These digital solutions aim to improve clinical outcomes while offering greater accessibility, convenience and reduced costs compared to traditional treatments.

Market Dynamics: Drivers & Restraints

Shift Towards Home-Based Care & Remote Patient Monitoring

The shift towards home-based care & remote patient monitoring is significantly driving the growth of the digital therapeutics for neurological disorders market and is expected to drive the market over the forecast period. Home-based care allows patients to receive treatment without the need for frequent hospital visits, particularly important for patients with chronic neurological conditions like Parkinson's Disease, Alzheimer's or Multiple Sclerosis. By leveraging digital therapeutics, patients can manage their symptoms at home using mobile apps, wearables or other digital platforms.

For instance, Akili Interactive's EndeavorRx, a digital therapeutic for ADHD, is an example of a solution that can be used at home, allowing patients to receive therapy without the need for in-clinic visits, reducing the burden on both patients and healthcare providers.

Remote patient monitoring helps overcome geographic barriers, allowing patients in rural or underserved areas to access advanced neurological care without traveling long distances. Digital therapeutics solutions, which include apps for symptom tracking and therapy adherence, can be used anywhere, bridging gaps in access to specialized care.

Digital therapeutics are designed to engage patients by offering tools like self-management apps, reminders, and personalized interventions. This improves patient adherence to therapy regimens, especially in chronic neurological conditions that require long-term management. The interactive and gamified nature of many digital solutions boosts engagement, making it easier for patients to stick with prescribed therapy regimens and track their progress regularly.

For instance, in October 2023, BeCareLink introduced a new quantitative and artificial intelligence (AI)-enabled app to support general neurologic exams for the screening and monitoring of neurologic diseases. Called BeCare Neuro Link, the new mobile application is intended for the remote, objective and comprehensive assessment of neurologic patients or those with potential neurologic conditions.

Data Privacy & Cybersecurity Concerns

Data privacy and cybersecurity are major concerns in the digital therapeutics for neurological disorders market, as these platforms rely on the collection, storage and analysis of sensitive patient data, including personal health information (PHI), cognitive assessments, and real-time health monitoring. Digital therapeutics platforms often store patient data in cloud-based systems or other online infrastructures, making them vulnerable to cyberattacks. A breach of sensitive health data could result in identity theft, financial fraud, or even medical fraud.

For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records are noticed. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month. In the year to August 31, 2024, there have been 491 data breaches of 500 or more records, and at least 58,668,002 records are known to have been breached. The average breach size in 2024 is currently 119,487 records and the median breach size is 4,109 records.

Segment Analysis

The global digital therapeutics for neurological disorders market is segmented based on product type, disease type, end-user and region.

Product Type:

The software therapeutics from the product type segment are expected to dominate the global digital therapeutics for neurological disorders market

Software therapeutics, primarily through mobile applications and web-based platforms, are accessible anytime, anywhere, making them a convenient option for patients. This ease of use is a major reason why software-based digital therapeutics are preferred in home-based care scenarios, especially for neurological conditions where ongoing management is required.

For instance, Cogstate's Cognigram is a software platform that provides cognitive testing for people with Alzheimer's disease and mild cognitive impairment. This platform enables patients to track cognitive performance remotely and interact with their healthcare provider, offering a more convenient and accessible solution than traditional in-clinic testing.

Software therapeutics are generally more cost-effective compared to traditional treatments that involve frequent doctor visits, hospitalizations, or long-term medication. By offering at-home solutions and reducing the need for in-person consultations, software therapeutics can lower the overall healthcare costs for both patients and healthcare providers. For instance, Pear Therapeutics' reSET-O, a prescription digital therapeutic for opioid use disorder, is an FDA-approved software solution that reduces the need for continuous in-person visits and provides remote support.

Geographical Analysis

North America is expected to hold a significant position in the global digital therapeutics for neurological disorders market

North America, and particularly the United States, benefits from a well-established regulatory framework through the FDA (Food and Drug Administration), which has streamlined the approval process for digital therapeutics. This regulatory clarity boosts market confidence and accelerates the adoption of digital therapeutics solutions for neurological disorders. For instance, The FDA's Digital Health Innovation Action Plan aims to promote innovation and expedite the approval of digital therapeutics. The approval of products like EndeavorRx (for ADHD) and reSET (for addiction treatment) demonstrates the regulatory readiness in North America to approve digital solutions for treating neurological conditions.

The prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy is rising in North America, driving the demand for digital therapeutics. The aging population in the United States and Canada is a major factor contributing to this increase. The number of people diagnosed with Alzheimer's is expected to grow significantly in North America due to the aging Baby Boomer population.

Digital therapeutic platforms that provide cognitive training, symptom tracking, and remote monitoring are increasingly sought after to manage the long-term care needs of these patients. For instance, according to the Alzheimer's Association, in the U.S. alone, 5.8 million people were living with Alzheimer's disease in 2020, and that number is expected to double by 2060. As the number of patients increases, so does the demand for digital health solutions to manage these conditions.

Competitive Landscape

The major global players in the digital therapeutics for neurological disorders market include Akili, Inc., Click Therapeutics, Inc., BigHealth, Apple Inc., MindMaze Inc, NeuroPace, Inc., NeurologyToolKit, Matoph Labs e.U., Fullpower Technologies, Inc., Neybox Digital Ltd. and among others.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global digital therapeutics for neurological disorders market report delivers a detailed analysis with 62 key tables, more than 56 visually impactful figures and 166 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Market Introduction and Scope

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. Executive Insights and Key Takeaways

2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Disease Type
2.5. Snippet by End-User
2.6. Snippet by Region

3. Dynamics

3.1. Impacting Factors
- 3.1.1. Drivers
  - 3.1.1.1. Shift Towards Home-Based Care & Remote Patient Monitoring
  - 3.1.1.2. Rising Prevalence of Neurological Disorders
- 3.1.2. Restraints
  - 3.1.2.1. Data Privacy & Cybersecurity Concerns
  - 3.1.2.2. Patient Adherence & Engagement Challenges
- 3.1.3. Opportunity
  - 3.1.3.1. Rising Technological Advancements
- 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

4.1. Market Leaders and Pioneers
- 4.1.1. Emerging Pioneers and Prominent Players
- 4.1.2. Established Leaders with Largest Selling Brand
- 4.1.3. Market Leaders with Established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Case Studies/Ongoing Research
4.5. Regulatory and Reimbursement Landscape
- 4.5.1. North America
- 4.5.2. Europe
- 4.5.3. Asia Pacific
- 4.5.4. Latin America
- 4.5.5. Middle East & Africa
4.6. Porter's Five Force Analysis
4.7. Supply Chain Analysis
4.8. Patent Analysis
4.9. SWOT Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders

5. Digital Therapeutics for Neurological Disorders Market, By Product Type

5.1. Introduction
- 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 5.1.2. Market Attractiveness Index, By Product Type
5.2. Software Therapeutics*
- 5.2.1. Introduction
- 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Wearable Devices

6. Digital Therapeutics for Neurological Disorders Market, By Disease Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 6.1.2. Market Attractiveness Index, By Disease Type
6.2. Neurodegenerative Disorders*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.2.3. Alzheimer's Disease
- 6.2.4. Parkinson's Disease
- 6.2.5. Multiple Sclerosis
- 6.2.6. Huntington's Disease
- 6.2.7. Others
6.3. Mental Health Disorders
- 6.3.1. Depression
- 6.3.2. Anxiety
- 6.3.3. Post-Traumatic Stress Disorder
- 6.3.4. Bipolar Disorder
- 6.3.5. Obsessive-Compulsive Disorder (OCD)
- 6.3.6. Others
6.4. Stroke & Cerebrovascular Disorders
6.5. Sleep Disorders
- 6.5.1. Insomnia
- 6.5.2. Sleep Apnea
- 6.5.3. Others
6.6. Cognitive Disorders
6.7. Others

7. Digital Therapeutics for Neurological Disorders Market, By End-User

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Neuro-Rehabilitation Centers
7.5. Homecare Settings
7.6. Others

8. Digital Therapeutics for Neurological Disorders Market, By Regional Market Analysis and Growth Opportunities

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 8.1.2. Market Attractiveness Index, By Region
8.2. North America
- 8.2.1. Introduction
- 8.2.2. Key Region-Specific Dynamics
- 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.2.6.1. U.S.
  - 8.2.6.2. Canada
8.3. Europe
- 8.3.1. Introduction
- 8.3.2. Key Region-Specific Dynamics
- 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.3.6.1. Germany
  - 8.3.6.2. U.K.
  - 8.3.6.3. France
  - 8.3.6.4. Spain
  - 8.3.6.5. Italy
  - 8.3.6.6. Rest of Europe
8.4. Latin America
- 8.4.1. Introduction
- 8.4.2. Key Region-Specific Dynamics
- 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.4.6.1. Mexico
  - 8.4.6.2. Brazil
  - 8.4.6.3. Argentina
  - 8.4.6.4. Rest of Latin America
8.5. Asia-Pacific
- 8.5.1. Introduction
- 8.5.2. Key Region-Specific Dynamics
- 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.5.6.1. China
  - 8.5.6.2. India
  - 8.5.6.3. Japan
  - 8.5.6.4. South Korea
  - 8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
- 8.6.1. Introduction
- 8.6.2. Key Region-Specific Dynamics
- 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking

10. Company Profiles

10.1. Akili, Inc.*
- 10.1.1. Company Overview
- 10.1.2. Product Portfolio
  - 10.1.2.1. Product Description
  - 10.1.2.2. Product Key Performance Indicators (KPIs)
  - 10.1.2.3. Historic and Forecasted Product Sales
  - 10.1.2.4. Product Sales Volume
- 10.1.3. Financial Overview
  - 10.1.3.1. Company Revenue's
  - 10.1.3.2. Geographical Revenue Shares
  - 10.1.3.3. Revenue Forecasts
- 10.1.4. Key Developments
  - 10.1.4.1. Mergers & Acquisitions
  - 10.1.4.2. Key Product Development Activities
  - 10.1.4.3. Regulatory Approvals, etc.
- 10.1.5. SWOT Analysis
10.2. Click Therapeutics, Inc.
10.3. BigHealth
10.4. Apple Inc.
10.5. MindMaze Inc
10.6. NeuroPace, Inc.
10.7. NeurologyToolKit
10.8. Matoph Labs e.U.
10.9. Fullpower Technologies, Inc.
10.10. Neybox Digital Ltd.